Haisco's two self-developed new drugs have secured overseas authorization, leading to a consecutive two-day rebound in the pharmaceutical sector! Hong Kong-listed innovative drug ETF Guangfa surged over 5% intraday, while the Hang Seng Biotechnology ETF Guangfa and the Innovative Drug ETF Guangfa rose over 4% intraday.

On the morning of June 24, 2026, pharmaceutical stocks continued to rise, rebounding for two consecutive days. In terms of individual stocks, Kailaiying led the way, while Pharmaron, CoronbioTech Bio, rose by over 7%, Taiyue Medical, Kanglong Huacheng, and Pharmaron Conde also followed suit. In terms of onshore ETFs, Hong Kong Biotech ETF GF Innovation rose by over 5%, while Hang Seng Biotechnology ETF GF and GF Innovator Drug ETF rose by over 4% during trading.